|
Variable
|
Contrast
|
HR (95% CI)
|
P value
|
|---|
|
Multivariate landmark analysis (n = 642)
|
|
Regimen
|
AT + HER2 vs. A + T
|
0.90 (0.37–2.20)
|
0.82
|
|
PC vs. A + T
|
1.28 (0.55–2.98)
|
0.56
|
|
A no T vs. A + T
|
1.25 (0.47–3.35)
|
0.66
|
|
Age
|
21–40 vs. 41–60
|
2.00 (1.05–3.82)
|
0.036
|
|
> 60 vs. 41–60
|
2.04 (1.01–4.15)
|
0.048
|
|
Postmenopausal
|
Yes vs. no
|
0.82 (0.43–1.59)
|
0.57
|
|
Stage
|
IIB vs. IIA
|
1.15 (0.60–2.23)
|
0.67
|
|
IIIA vs. IIA
|
0.73 (0.24–2.15)
|
0.56
|
|
IIIB vs. IIA
|
2.06 (0.87–4.88)
|
0.099
|
|
IIIC vs. IIA
|
2.26 (1.11–4.61)
|
0.024
|
|
Grade
|
III vs. I/II
|
0.67 (0.35–1.28)
|
0.22
|
|
Subtype
|
HER2-amplified vs. TN
|
0.56 (0.25–1.28)
|
0.17
|
|
HR vs. TN
|
1.00 (0.46–2.22)
|
0.99
|
|
Adjuvant chemotherapy
|
Yes vs. no
|
1.33 (0.64–2.77)
|
0.45
|
|
Adjuvant hormone therapy
|
Yes vs. no
|
0.75 (0.39–1.45)
|
0.40
|
|
Adjuvant radiation treatment
|
Yes vs. no
|
0.65 (0.34–1.22)
|
0.18
|
- Abbreviations: A no T Adriamycin-based therapy alone, A + T Adriamycin plus taxane, AT + HER2 HER2-targeted therapy, PC Provider choice, HR Hormone receptor, TN Triple-negative breast cancer
- Italicized values are statistically significant
